TKT and chronic myelogenous leukemia, BCR-ABL1 positive: Clinical responses and outcomes for patients with CML were remarkably improved after the introduction of a small molecule TK inhibitor of BCR-ABL1, which effectively blocks all the hyperactivated pathways and results in CML cell death [27,28].